GMP IPO Watch
Himalaya Nutravedics India IPO Opens for Subscription
Himalaya Nutravedics India IPO opened today, September 22, 2026, and will remain open until September 24. The IPO is a book-built SME issue consisting entirely of a fresh issue of 24,99,600 equity shares. The company aims to raise up to ₹26.50 crore through the issue, with the shares proposed to list on BSE SME.
| Particular | Details |
|---|---|
| IPO Name | Himalaya Nutravedics India IPO |
| IPO Dates | Sep 22–24, 2026 |
| Price Band | ₹100–₹106 |
| Issue Size | ₹26.50 Cr |
| Issue Type | Fresh Issue |
| Fresh Shares | 24,99,600 |
| Lot Size | 1,200 Shares |
| Retail Minimum | 2 Lots |
| Minimum Investment | ₹2,54,400 |
| Listing Platform | BSE SME |
| Allotment | Sep 25, 2026 |
| Refund / Demat | Sep 28, 2026 |
| Listing | Sep 29, 2026 |
| Lead Manager | Nirbhay Capital Services |
| Registrar | KFin Technologies |
Himalaya Nutravedics India IPO GMP Today
The latest grey-market information does not show a firm quoted GMP for Himalaya Nutravedics India IPO. One IPO tracker reported GMP at ₹0, while another current tracker lists the GMP as not quoted. Investors should therefore treat the GMP as ₹0/not quoted rather than assuming a premium.
| GMP Particular | Latest Update |
|---|---|
| GMP | ₹0 / Not Quoted |
| Upper Price Band | ₹106 |
| Indicative Price | ₹106 if GMP remains ₹0 |
| Indicative Premium | 0% |
GMP is unofficial and unregulated, and it can change before listing.
Himalaya Nutravedics India IPO Subscription Status
The IPO opened today, so category-wise subscription figures were not available in the latest updates checked. The issue has a reservation structure of up to 50% for QIBs, at least 15% for NIIs and at least 35% for retail investors.
| Category | Reservation |
|---|---|
| QIB | Up to 50% |
| NII | At least 15% |
| Retail | At least 35% |
Subscription figures are expected to develop during the three-day bidding period.
Himalaya Nutravedics India Business Overview
Himalaya Nutravedics India is a Hyderabad-based Ayurvedic and nutraceutical manufacturer. The company develops, manufactures, markets and distributes Ayurvedic and nutraceutical formulations, while also undertaking third-party contract manufacturing for other healthcare businesses.
Its product portfolio includes softgel and hardgel capsules, tablets, liquid orals, medicated oils and protein powders. Products address areas including digestive health, immunity, metabolic health, reproductive and maternal care, paediatric applications, musculoskeletal needs and general wellness.
Himalaya Nutravedics India IPO Financial Performance
The company has recorded strong growth in revenue and profitability over the last three financial years. Revenue increased from ₹14.43 crore in FY2024 to ₹43.07 crore in FY2026, while PAT increased from ₹0.43 crore to ₹7.39 crore.
| Financial Year | Revenue | PAT |
|---|---|---|
| FY2024 | ₹14.43 Cr | ₹0.43 Cr |
| FY2025 | ₹21.00 Cr | ₹2.23 Cr |
| FY2026 | ₹43.07 Cr | ₹7.39 Cr |
FY2026 EBIT was approximately ₹7.78 crore, while net worth stood at about ₹16.38 crore and debt at around ₹5.13 crore.
Himalaya Nutravedics India IPO Key Ratios
The company's FY2026 profitability ratios show a significant improvement alongside the increase in revenue and earnings.
| Financial Indicator | FY2026 |
|---|---|
| ROE | ~45.11% |
| ROCE | ~36.41% |
| Debt-to-Equity | ~0.31 |
| PAT Margin | ~17.16% |
| EBITDA Margin | ~18.82% |
| Net Worth | ₹16.38 Cr |
| Debt | ₹5.13 Cr |
The reported post-issue valuation at the upper price band also places the company at a double-digit earnings multiple based on FY2026 earnings.
Himalaya Nutravedics India IPO Objects of the Issue
The company plans to use the IPO proceeds primarily for working capital requirements and expansion of its branding and marketing activities. The funds are intended to support business growth and strengthen the company's market presence.
| IPO Objective | Amount / Purpose |
|---|---|
| Working Capital | ₹13.75 Cr |
| Branding & Digital Marketing | ₹7.50 Cr |
| General Corporate Purposes | Balance funds |
Himalaya Nutravedics India Business Model
The company follows a combination of its own branded products and third-party contract manufacturing. This model gives it exposure to both direct product sales and manufacturing requirements from other healthcare companies.
Its manufacturing portfolio covers multiple dosage forms, allowing the company to serve different categories within the Ayurvedic and nutraceutical market. The company is also expanding its branding and sales activities, which is one of the stated uses of IPO proceeds.
Himalaya Nutravedics India IPO Strengths
Himalaya Nutravedics has expanded its revenue and profit base significantly between FY2024 and FY2026. Its presence across Ayurvedic products, nutraceuticals and contract manufacturing provides multiple sources of business.
The company also operates in a market where demand for wellness, nutrition and traditional healthcare products has expanded. Its relatively low reported debt-to-equity ratio and improved profitability are additional financial points investors may monitor.
Himalaya Nutravedics India IPO Risks
The company operates from a manufacturing setup where dependence on production facilities, suppliers and key customers can affect business continuity and margins. Customer concentration is also an important risk highlighted in available IPO analysis.
Working-capital requirements remain significant, and the company has experienced negative operating cash flows in some periods. Competition in Ayurvedic, nutraceutical and contract manufacturing markets could also affect pricing and margins.
As an SME-listed company, the shares may also experience lower liquidity and higher price volatility after listing compared with larger mainboard companies.
Himalaya Nutravedics India IPO Important Dates
The IPO opened on September 22 and will close on September 24, 2026. The basis of allotment is scheduled for September 25, refunds and demat credit are expected on September 28, and listing is scheduled for September 29 on BSE SME.
| IPO Event | Date |
|---|---|
| IPO Opening | Sep 22, 2026 |
| IPO Closing | Sep 24, 2026 |
| Allotment | Sep 25, 2026 |
| Refund / Demat Credit | Sep 28, 2026 |
| Listing | Sep 29, 2026 |
Himalaya Nutravedics India IPO Latest News Summary
Himalaya Nutravedics India IPO has opened with a price band of ₹100–₹106 and an issue size of ₹26.50 crore. The IPO is entirely a fresh issue and will be listed on BSE SME.
The latest GMP is currently ₹0 or not firmly quoted, while subscription data is still developing because bidding began today. The company reported FY2026 revenue of ₹43.07 crore and PAT of ₹7.39 crore, compared with ₹21 crore revenue and ₹2.23 crore PAT in FY2025.
The IPO will remain open until September 24, with allotment expected on September 25 and listing scheduled for September 29.
Disclaimer: IPO GMP is an unofficial and unregulated market indicator and can change at any time. Subscription figures are updated during the IPO period and may vary depending on the reporting time. This article is for informational purposes only and should not be considered investment advice.
